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Abstract 
Objective. We present a meta-analytic method that combines information on treatment effects 
from different instruments from a network of randomized trials to estimate instrument relative 
responsiveness. 
Study design. Five depression-test instruments (Beck Depression Inventory (BDI I/II), Patient 
Health Questionnaire (PHQ9), Hamilton Rating for Depression (HAMD 17 and 24-item), 
Montgomery-Asberg Depression Rating (MADRS)), and three generic quality of life measures 
(EuroQoL (EQ-5D); SF36 Mental (SF36-MCS) and Physical Component Summaries (SF36-PCS)) 
were compared. Randomized trials of treatments for depression reporting outcomes on any 
two or more of these instruments were identified. Information on the within-trial ratios of 
standardized treatment effects was pooled across the studies to estimate relative 
responsiveness. 
Results.  The between-instrument ratios of standardized treatment effects vary across trials, 
with a coefficient of variation of 13% (95% CrI 6%-25%). There were important differences 
between the depression measures, with PHQ9 being the most responsive instrument, and BDI 
the least. Responsiveness of the EQ-5D and SF36-PCS were poor. SF36-MCS performed 
similarly to depression instruments.  
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Conclusion.  Information on relative responsiveness of several test instruments can be pooled 
across networks of trials reporting at least two outcomes, allowing comparison and ranking of 
test instruments that may never have been compared directly. 
Keywords: Relative Responsiveness, test instruments, meta-analysis, depression.  
1. Introduction 
The responsiveness of a measuring instrument is broadly understood as its ability to detect 
meaningful changes in a patient’s clinical state. However, there is little consensus on the 
mathematical way to determine the magnitude of change and a variety of indices have been 
used.  
Comparative studies of the responsiveness of patient- and clinician-reported outcomes are 
undertaken to improve the assessment of interventions and inform the choice of outcome 
measure for future studies. The responsiveness of depression-specific instruments reported by 
either patients or clinicians, have been examined mainly in isolated studies.  A variety of 
definitions exist [1, 2]. Some of them are based on assessing longitudinal within-patient 
changes in clinical condition over time, others on the ability to discriminate cross-sectionally 
between groups of patients, including patients in different arms in randomized trials.  Lack of 
comparability in metrics poses challenges for evaluating interventions, comparing effects across 
different studies and designing new studies.  
In this paper we focus on responsiveness to treatment in the context of clinical trials, but the 
same methods can be extended to longitudinal measures (see discussion). Measures of the 
relative responsiveness to the changes caused by interventions are of particular significance for 
the evaluation of therapeutic interventions. More importantly, relative instrument 
responsiveness measurers can help guide the choice of outcome measures in clinical trials. 
More responsive outcomes permit smaller trials at a given power, improving efficiency and 
reducing costs.  
Whether longitudinal or cross-sectional designs are used, responsiveness is measured 
predominantly by “effect size” statistics, which are standardized by dividing the mean 
longitudinal change or a mean treatment difference by an estimate of the relevant standard 
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deviation (SD) [3-5]. The resulting standardized estimates, also known as “standardized effect 
sizes” are among the recommended criteria for identifying and selecting instruments by the 
Patient reported Outcomes Measurement Group [6].  The two main statistical standardization 
approaches are the Cohen’s d [7] which involves division by a pooled SD, and Hedge’s g [8] 
which includes a bias correction due to small sample size that is important for sample sizes less 
than 10 [9]. 
Significance of change scores are typically computed from paired t-tests. The ratio of effect 
sizes from two instruments is the ratio of paired t-tests. The ratio of the effect sizes from two 
test instruments can be interpreted as a measure of relative responsiveness. It estimates the 
extent to which one scale is more or less efficient at detecting change over time relative to 
another scale  [10] .  
Papers exploring responsiveness of one or more measures can be found in every field of 
medicine [11]. However, with some exceptions [12-14], the literature on comparative 
responsiveness of test instruments does not attempt to pool estimates across studies. Here we 
develop a formal meta-analytic approach, which pools within-trial information on the ratios of 
standardized effect sizes, across a connected network of trials. This allows investigators to draw 
conclusions about the relative responsiveness of several outcomes measures, including those 
that may never have been compared directly, and to rank test instruments in terms of 
responsiveness. 
We begin by describing an illustrative dataset of trials of treatments for depression, in which 
outcomes were reported on five disease-specific and three generic Quality of Life (QoL) 
measures. We then explain the statistical methods, which have been used previously for 
simultaneously estimating treatment effects and “mappings” between outcomes on different 
scales [15, 16]. These methods derive from a common factor theory of test instruments [17, 
18].  In the discussion section we describe the properties of our method, the assumptions being 
made, and its limitations. We also consider the proposed methods in relation to previous 
methodological work on responsiveness.  
2. METHODS 
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2. 1 Illustrative dataset 
A generic search for depression outcomes was initially conducted in May 2011 including all 
measures of depression, anxiety and quality of life available in studies on the Cochrane 
Depression Anxiety and Neurosis (CCDAN) Review Group's register.  Details of CCDAN's generic 
search strategies can be found on the Group‘s website1. This search identified 75 studies 
reporting statistics with at least two of the following eight test instruments, five disease-specific 
and three health-related Quality of Life (QoL) scales: the Beck Depression Inventory (BDI I/II) 
[19], Patient Health Questionnaire (PHQ9) [20], Hamilton Rating for Depression scale (HAMD 17 
and 24-item) [21], Montgomery-Asberg Depression Rating Scale (MADRS) [22]; EQ-5D or 
EuroQol [23]; and the “short-form” SF36 Mental and Physical Components Summaries [24]. 
Among these we identified 31 placebo- and/or usual care controlled studies with clearly 
defined treatment and control groups that reported either statistics at follow-up for each of 
comparison groups (i.e. means, SDs and sample sizes), or change score statistics (mean, SD, and 
sample size). Where both were reported, the follow-up scores were used in the analysis.  
One of the 31 studies reported outcomes separately for patients at two levels of depression. 
We treated this as two independent trials, effectively giving 32 studies. Eleven were drug trials, 
and the remaining were studies of psychological therapies (psychotherapy, cognitive behavioral 
therapy, psychoeducation and problem solving in primary care settings). There were also four 
studies with assorted treatments including regimens involving monitoring or choice of 
pharmacological treatment, herbal medicine, and other treatments. A detailed description and 
citation listing can be found in the Supplementary materials (A.1). The treatment effects are 
expressed as differences relative to the control arm (Table 1). It should be noted that the 
criteria for study inclusion is far more liberal than would be appropriate for studies of relative 
treatment effects, as we will be pooling information on effect size ratios from a very wide range 
of treatments (see discussion).  
                                                     
1
 http://cmd.cochrane.org/search-strategies-identification-studies 
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Table 1: Treatment effects, their standard errors and pooled SD at follow-up, in the 32 included Studies for treatment of depression. SE Standard Error of 
mean treatment effect, SD standard deviation at follow-up or change score. (N control and N Treat numbers of patients in control and treatment arms, N 
number of observations for each outcome (including different arms contributing data on the same outcome). 
Study  
Reference  
(Total N=111) 
(N control / N Treat.) 
BDI 
Mean (SE) 
SD (pooled) 
N=25 
PHQ9 
Mean (SE) 
SD (pooled) 
N=9 
HAMD17 
Mean (SE) 
SD (pooled) 
N=35 
HAMD24 
Mean (SE) 
SD (pooled) 
N=2 
MADRS 
Mean (SE) 
SD (pooled) 
N=21 
EQ5D 
Mean (SE) 
SD (pooled) 
N=4 
SF36-Mental 
Mean (SE) 
SD (pooled) 
N=9 
SF36-Physical 
Mean (SE) 
SD (pooled) 
N=6 
1. AIM 2002 
 
-3.40 (0.84) -3.30 (1.09) 
      (93/89) 
 
SD=5.70 SD=7.37 
     2. Carney 2006 1.30 (1.80)
 
0.60 (1.20) 
         (60/62) SD=9.96 
 
SD=6.59 
     3. Ijff 2007 -2.80 (2.50) 
 
-4.50 (2.24) 
         (20/20) SD=8.95 
 
SD=8.67 
     4. Konig 2009 1.87 (1.20) 
    
-0.02 (0.07)
      (150/156) SD=10.46 
    
SD=0.65 
  5.MIND IT (2002 b -3.78 (2.13) 
 
-2.44 (1.26)
        (41/37) SD=8.07 
 
SD=6.27 
     6. Moak 2003 -2.10 (2.19) 
 
-1.00 (1.48) 
         (44/38) SD=10.12 
 
SD=6.63 
     7. Ooskooilar 2006 
  
-1.80 (0.85) 
 
-3.30 (1.13)
       (199/198) 
  
SD=8.45 
 
SD=11.27 
   8. Pope 2010 
  
-0.60 (1.58) 
 
-0.50 (2.05) 
       (34/40) 
  
SD=6.91 
 
SD=8.89 
   9. SADHART 2002 -0.70 (0.85)
 
-0.80 (0.57) 
         (183/184) SD=8.13 
 
SD=5.42 
     10. de-Battista 2010 
 
-4.30 (1.74)
  
-5.40 (2.98)
        (44/34) 
 
SD=7.76 
  
SD=13.30 
   11. ARISE-RD 2003 
  
-5.70 (0.46)
 
-8.20 (0.63) 
       (489/383) 
  
SD=6.62 
 
SD=9.11 
   12. FAVA 2005 
  
-1.20 (0.35) 
 
-1.40 (0.77) 
       (149/151) 
  
SD=4.32 
 
SD=8.67 
   13. Mannel 2010 
 
-1.40 (0.59) -1.10 (0.61) 
         (100/100) 
 
SD=4.20 SD=4.30 
     14. IPCRESS 2009 -7.50 (1.73)
    
0.07 (0.03)
      (97/113) SD=12.32 
    
SD=0.21 
  15. COBALT 2013 -5.60 (1.34) -3.00 (0.65)
          (213/206) SD=13.65 SD=6.65 
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16. Oriordan-2007 
  
-2.50 (0.85) -2.80 (1.16) -3.20 (1.37) 
      (155/146) 
  
SD=7.35 SD=9.99 SD=11.81 
   17. CREATE 2006 -3.30 (1.27)
 
-2.19 (0.90) -3.61 (1.19) 
       (142/142) SD=10.68 
 
SD=7.61 SD=9.99 
    18. MIND-IT 2002 a 0.80 (0.85) 
     
1.10 (1.11) 0.00 (0.81)
   (86/132) SD=6.66 
     
SD=8.06 SD=5.88 
19. THREAD 2009 -2.16 (1.33) 
 
-2.49 (0.81)
   
7.56 (3.03) 
    (90/96) SD=9.06 
 
SD=5.49 
   
SD=20.58 
 20. CADET 2013 
 
-1.60 (0.63)
    
3.90 (1.31) 0.20 (1.20)
    (275/230) 
 
SD=7.03 
    
SD=14.50 SD=13.53 
21. Dowrick 1996 -2.49 (1.33)
     
5.83 (2.95) 
 21. Dowrick 1996 -0.71 (1.39) 
     
6.37 (3.09) 
     (139/98;80) SD=10.01 
     
SD=22.31 
 22. Fabre 1992 b 
  
-4.56 (1.90)
 
-4.30 (1.95)
   22. Fabre 1992 b 
  
-6.07 (1.89) 
 
-6.98 (1.94) 
       (36/37;38) 
  
SD=8.11 
 
SD=8.33 
   23. Pedersen 2003 a 
  
-1.30 (0.82) 
 
-2.40 (1.21) 
   23. Pedersen 2003 a 
  
  -2.40 (0.81) 
 
-3.70 (1.20) 
       (117/96;99) 
  
SD=5.96 
 
SD=8.78 
   24. Demitrack 2001 
  
-3.12 (0.78) 
 
-3.38 (1.11) 
   24. Demitrack 2001 
  
-1.14 (0.96) 
 
-2.23 (1.45) 
       (68/66;33) 
  
SD=6.35 
 
SD=9.21 
   25. Serfaty 2009 -1.91 (1.99)
    
0.07 (0.07)
  25. Serfaty 2009 -0.03 (1.86) 
    
0.09 (0.06) 
     (59/58;55) SD=10.40 
    
SD=0.34 
  26. Titov 2010 -10.86 (2.22) -5.39 (0.94)
      26. Titov 2010 -11.56 (2.29) -5.68 (0.96) 
          (40/41;46) SD=10.41 SD=4.33 
      27. Richards 2008 
 
-5.02 (1.99) 
    
0.42 (2.86) 1.69 (3.29)
27. Richards 2008 
 
-3.55 (2.05) 
    
1.68 (2.74) 1.79 (3.32) 
    (27/35;34) 
 
SD=7.58 
    
SD=10.87 SD=11.95 
28. Kasper 2006 -4.30 (1.20)
 
-4.80 (1.11)
 
-5.30 (1.43)
 
9.70 (2.55) 3.60 (2.11) 
28. Kasper 2006 -4.60 (1.17) 
 
-5.60 (1.07) 
 
-7.00 (1.44) 
 
11.30 (2.36) 1.60 (2.27) 
    (81/124;119) SD=8.59 
 
SD=7.20 
 
SD=9.59 
 
SD=19.12 SD=16.48 
29. Goldstein 2004 
  
-2.43 (0.85) 
 
-1.94 (1.23) 
   29. Goldstein 2004 
  
-3.62 (0.74) 
 
-3.30 (1.09) 
   29. Goldstein 2004 
  
-1.23 (0.78) 
 
-1.58 (1.20) 
        (88/84;86;84) 
  
SD=7.41 
 
SD=10.77 
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30. Dimidjian 2004_1 -1.74 (3.07) 
 
-1.64 (1.61) 
     30. Dimidjian 2004_1 -0.79 (2.42) 
 
0.35 (1.78) 
     30. Dimidjian 2004_1 0.65 (3.15) 
 
-0.48 (1.87) 
          (19/17;28;15) SD=9.09 
 
SD=5.63 
    31. Dimidjian 2004_2 -5.68 (3.31) 
 
-2.96 (2.31) 
     31. Dimidjian 2004_2 -8.11 (3.29) 
 
-3.42 (1.97) 
     31. Dimidjian 2004_2 -1.50 (4.23) 
 
-3.23 (2.22) 
         (22/22;38;21) SD=11.82 
 
SD=7.26 
     32. Loo 2002 a 
  
-2.25 (1.17) 
 
-3.27 (1.42)
   32. Loo 2002 a 
  
-2.17 (1.16) 
 
-2.01 (1.48) 
   32. Loo 2002 a 
  
-0.64 (1.21) 
 
-1.52 (1.48) 
   32. Loo 2002 a 
  
-2.57 (1.18) 
 
-3.64 (1.41) 
       (136/144;136;135) 
  
SD=8.44 
 
SD=9.24 
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A network diagram (Figure 1) shows how many trials report each pair of test outcomes.  
HAMD17 and BDI were the most common. The proposed method requires that each of the 
tests included are “connected” to one or more other tests by at least one trial. There were 
25 2-outcome studies, 6 3-outcome, and one 5-outcome study. There were 20 studies with 
2 arms, 8 with 3 arms, 3 with 4 arms and 1 with 5 arms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Network of outcomes from the 32 studies considered. Each node represents each 
outcome with size proportional to the number of trials that include the given outcomes. The 
thickness of each edge is proportional to the total sample size in each pairwise connection. 
The data used in the study were the mean treatment differences after 12 weeks follow-up, 
or as close to that as possible. Treatment differences and their standard errors were based 
on mean difference at follow-up if available; otherwise mean differences in change-from-
baseline. Similarly, the pooled standard deviation at follow-up was used for standardization 
if available; otherwise the pooled standard deviation on the changes scores (Table 1).  
2.2 Statistical methods 
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We use statistical models developed previously [15, 16]  to allow for simultaneous 
estimation of  both treatment effects on continuous outcomes and “mappings” between 
treatment effects in a Bayesian framework. The mappings are simply ratios of the 
underlying treatment effects on their original scales. Here we apply the same model to 
standardized effects, interpreting the mappings between standardized effects as relative 
responsiveness ratios.  
The model for the treatment effect was a conventional random effects model with study 
effects 1i drawn from a normal distribution with mean   and variance
2 , whilst i denote 
study.  Under the assumption of no difference in efficacy between the different treatments 
for depression, any variation between treatments would be absorbed into the between-trial 
variation and (see discussion). 
The index 1 on 1i indicates that this is the standardized treatment effect on the BDI scale; 
any of the measurement instruments could be selected as outcome 1, but BDI is chosen as it 
is one of the most frequently used tests. The fact that BDI is the only outcome that can be 
compared directly to each of the other measures (see Figure 1) also favors its adoption as 
the reference outcome, as this improves stability and convergence in Markov chain Monte 
Carlo (MCMC) estimation (see below). Two models for the relationship between the test 
instruments were examined. In the first it is assumed that the treatment effects on test 
instruments h and k, ,ih ik   are in the same fixed ratio in every trial (fixed mapping ratio): 
,  for all ik h k
ih
i



                                                                                                   (1) 
In a second model (random mapping ratio) this assumption is relaxed, and ratios are 
allowed to vary around their mean value: 
2
, ,,   ~ ( , )
ik
i h k i h k h k hk
ih
N

   

                                                                         (2) 
In the random mapping model, we have proposed a constant between-trials coefficient of 
variation (CV), , which is the between-trials standard deviation of mapping coefficients 
divided by the mean mapping [15, 16], so that 2hk  = 
2 2
h k  .  An important feature of both 
models, which follows from (1) and (2) is that the ratios must be transitive, and invertible: 
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1
= ,   and  x z x y y z x z
z x
   

   

                                                                     (3) 
As a result of these logical constraints, if there are M different measurement instruments (in 
this example M=8), there are M(M-1)/2 (=28) ratios to be estimated, but it is only necessary 
to estimate M-1 (=7) basic relative responsiveness parameters [25] , for example the ratios 
of the first with the other M-1, as the remaining 21 parameters are functions of them as 
shown in (3). The fixed and random relative responsiveness models can be compared in 
terms of goodness of fit.  
Our Bayesian approach places vague prior distributions on the pooled mean treatment 
effect,  the between-trial standard deviation of treatment effects, 2  the M-1 mapping 
coefficients 1 h  , and, in the random mapping ratio model, the between-trial CV . 
Technical details of the prior distributions are given in Supplementary materials. 
Correlations between the effect sizes from the same trial must be taken into account. These 
can be derived from correlations between original test scores, as described previously [15, 
26].Because correlations are not generally reported in trials, we have assumed a correlation 
matrix based on external information (Table 2). The correlations between the psychiatric 
measures were based on Handbook of Psychiatric Measures [27] and a recent publication 
on QoL measures in depression [27]. We examined sensitivity of results to the assumed 
correlations, by raising or lowering them by a factor of 40%.  
Table 2.  Assumed within-study correlations between variables. Based on Handbook of 
Psychiatric Measures  [27] and a recent HTA repost on QoL measures in depression [39].  
 BDI I/II PHQ9 HAMD17 HAMD24 MADRS EQ5D SF36MCS SF36PCS 
BDI I/II 1 0.60 0.65 0.65 0.65 -0.40 -0.65 -0.05 
PHQ9  1 0.60 0.60 0.60 -0.35 -0.60 -0.05 
HAMD17   1 0.65 0.65 -0.40 -0.65 -0.05 
HAMD24    1 0.65 -0.40 -0.65 -0.05 
MADRS     1 -0.40 -0.65 -0.35 
EQ5D      1 0.40 0.50 
SF36MCS       1 0.10 
SF36PCS        1 
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2.3 Statistical estimation 
Estimation was carried out by Markov Chain Monte Carlo (MCMC) using WinBUGs [28]     
Goodness of fit was assessed via the posterior mean Residual Deviance ( D ) as a global 
goodness of fit statistic  [29]. Convergence, based on statistical criteria [30], was achieved 
within 50,000 iterations. Posterior summaries were based on 100,000 samples over 5 chains 
with different starting values and after having discarded the first 200,000 samples to arrive 
at estimates with Monte Carlo error less than 5% of the sample standard deviation for all 
parameters.  
3. RESULTS 
Posterior summaries of estimated parameters for the fixed and random relative 
responsiveness ratios are compared in Table 3. Both fixed and random ratio models fit the 
data well, withD  = 112.3 and 107.7 respectively. In a well-fitting model D  should be 
approximately equal to the total number of observations, which are 111 in this dataset. The 
posterior means of the relative responsiveness ratios in the fixed and random ratio are 
extremely close. The posterior median of the between-study CV of the relative 
responsiveness ratios is 13%. The CV quantifies the amount of between-study variation of 
treatment ratios or relative instrument responsiveness and is a direct way of testing 
whether instrument relative responsiveness varies across studies or can be thought as fixed 
and equal to 1. The fixed ratio model assumes that instrument relative responsiveness is 
fixed to 1. In other words under the fixed ratio model, the test instruments are assumed as 
equal responsive relative to the chosen reference instrument. This assumption is relaxed 
under the random ratio model. The between-study variation in instrument relative 
responsiveness is then quantified by the CV parameter.  The CV summarizes this variation by 
expressing the between-study SD of relative responsiveness ratios relative to their mean 
values and was found to be 13% of their mean values.  This is a moderate value, but the 95% 
Credible Interval (CrI) of 6%-25% is relatively far from zero, indicating statistical grounds for 
preferring the random ratio model.  
We can interpret the relative responsiveness ratios as follows: taking HAMD17 as an 
example and using the random ratio model, one SD unit treatment effect of BDI is on 
average equivalent to 1.33 SD unit effect on HAMD17. In other words, HAMD17 is more 
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responsive to treatment changes than BDI by a factor of 1.33 (95% CrI: 1.04 – 1.67). 
Evidently, PHQ9 is the most responsive to treatment, and SF-36 PCS the least (Table 3). 
Table 3. Posterior summaries of treatment effect, between-trials variation, relative 
responsiveness ratios, and ranking of relative responsiveness ratios (rank 1 is the most 
responsive).   
 
 Fixed Ratios 
 
Mean (SD) 
Random Ratios 
 
Mean (SD) 
Ranking estimates: 
random ratio model 
2.5%   50%   97.5% 
Mean treatment effect  
on BDI ( ) 
-0.27 (0.04) -0.26 (0.04)  
 
 
 Median   [95% CI] Median   [95% CI]  
Between-trial sd ( ) 0.15 [0.10, 0.23] 
 
0.15  [0.09, 0.23]  
Responsiveness  
relative to BDI 
BDI (reference) 
 
 
1                - 
 
 
1                - [4   6   7] 
PHQ9 1.52      [1.17   2.05] 1.53       [1.14   2.14] [1   1   4] 
HAMD17 1.31      [1.04   1.69] 1.31       [1.02   1.72] [1   3   5] 
HAMD24 1.31      [0.80   2.07] 1.30       [0.75   2.22] [1   3   7] 
MADRS 1.29      [1.02   1.69] 1.26       [0.94   1.71] [1   4   6] 
EQ5D -0.59   [-1.24   -0.12] -0.58    [-1.35   -0.08] [3   7   8] 
SF36MCS  -1.20   [-1.62   -0.89] -1.22   [-1.72   -0.87] [1   4   6] 
SF36PCS -0.36   [-0.92   -0.03] -0.37   [-0.94   -0.07] [7   8   8] 
Between-trial CV( ) - 0.13    [0.06, 0.25]  
Mean Residual Deviance 
 (D ) 
112.3 107.7  
 
 
The mean (standardized) treatment effect on the BDI scale is -0.26 with posterior standard 
deviation (0.04). This has no useful interpretation as it is an average of an arbitrary mixture 
of active treatments against placebo or waitlist. However, in comparison the method allows 
investigators to report treatment effects on any of the (standardized) scales [16, 31] (A.2). 
For example the treatment effect on the standardized HAMD17 scale will be -0.26 times 
1.33.  
The posterior densities of the relative responsiveness ratios relative to BDI can be found in 
Figure 2. (For ease of interpretation we have ignored the signs of the ratios which simply 
denote that effective treatment produces an increase on EQ-5D, SF-36 MCS and PCS, and a 
decrease on PHQ9, BDI, HAMD17, HAMD24, and MADRS).  
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Figure 2: Distribution densities of the relative responsiveness ratios of each test instrument 
relative to BDI over-laid on the region of common support. (Note: signs have been ignored)   
 
The “rankogram” (Figure 3) and the Box Plot (Figure 4) give a better impression of the 
reliability of the differences between the instruments in responsiveness. These show that 
there is considerable uncertainty regarding each instrument’s rank. For example PHQ9 is the 
best (most responsive) but there is still a 25% chance that it is ranked 3rd or lower. All 
instruments with the exception of EQ5D have very little chance of being less responsive 
than SF36PCS. The relative responsiveness of the 5 depression-specific measures and 
SF36MCS is of particular interest. The difference between the cumulative probabilities of 
the best (PHQ-9) and worst (BDI) is 84%. This can be referred as the distribution of the 
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expected differences between ranked probabilities drawn from a uniform distribution [32]. 
The probability of finding a difference this large is less than 5%. 
 
Figure 3: Rankograms of instrument sensitivity to treatment under the random mapping 
model.    
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Figure 4: Box-plot comparing instrument specific posterior distribution of rankings. 
Sensitivity of results to the correlation between test scores was assessed by raising or 
lowering correlations by 10% and 40%. In both models this has very little effect on the mean 
treatment effect, the between trials variation in treatment effects, or the treatment ratios. 
Only for large increases (40%) in the correlation matrix we noticed an increase to the 
coefficient of variation of mapping of 6% [i.e. from 13% to 19%] in the random ratios model. 
However, even this unrealistic variation in the correlations, induced changes in the mean 
relative responsiveness ratios which ranged between 0.02 – 0.06.  
 4.  Discussion 
Comparative instrument responsiveness studies are needed to improve the assessment of 
mental health interventions and their health economic evaluation as well as inform optimal 
study design in mental health. This paper demonstrates a new meta-analytic method for 
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assessing the relative responsiveness of test instruments from a connected network of 
trials. The method, in essence, carries out an across-trial pooling of the within-trial 
information on the ratios of standardized effect sizes, interpreting these ratios as measures 
of relative responsiveness. It takes advantage of the logical requirement that the true ratios 
must be transitive, meaning that the ratio of test outcomes A and C is the product of the A: 
B and B: C ratios, and uses this to facilitate an efficient and coherent pooling of the ratio 
information.  
The substantive findings from the study are limited by its small size. However, previous 
psychometric comparisons of different test instruments for depression have been generally 
restricted to comparing a very small number of tests, usually two [33-35], based on single 
studies. Where meta-analysis of several studies has been carried out, this was only when 
every study included all the tests [13, 14].  Our finding that PHQ-9 was superior to BDI in 
responsiveness confirms a previous reports making this comparison [35].  However, its high 
ranking is somewhat surprising as PHQ-9 is a very short questionnaire with only 9 items. 
According to standard Measurement Theory greater precision and less measurement error 
should be associated with longer tests with more items [36]. On the other hand, the brevity 
of the PHQ-9 is considered an advantage for monitoring depression outcomes, as patients’ 
responses may deteriorate in quality if instruments are too long [37].  
The finding that generic measures such as EQ-5D and SF-36 PCS are very insensitive to 
differences caused by treatments for depression is expected from the literature [38, 39]. 
Relatively high correlations between standard depression test instruments and SF36 mental 
health have been observed before [40, 41]. A number of studies have showed that SF36-
MCS can be a useful screening test for depression based on studies of different sub-
populations [42-46]. 
It is of some interest that there was evidence that relative responsiveness ratios vary from 
trial to trial though the coefficient of variation was modest, 13%. Similar degrees of 
between-trial variation have been observed in measures of social anxiety [16] and 
ankylosing spondylitis [15] .  A certain degree of variation is to be expected from the fact 
that the relationships between the different outcomes are only approximately linear, with 
some test instruments more sensitive to differences at one end of the continuum, and some 
at the other [47]. It follows that any heterogeneity in depression severity can be expected to 
generate random variation in relative responsiveness ratios. Furthermore, variation 
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between studies in the proportion of total variance attributable to the target construct 
(depression) is also likely to generate variation in relative responsiveness.  
Our method assumes that test instruments have the same responsiveness regardless of 
treatment. There have been suggestions that the MADRS scale is specifically responsive to 
the effects of tricyclic amines [13], and that BDI, MDRS and HAMD instruments are 
differentially responsive to SSRIs and nortriptyline [45]. There are also indications that the 
HAMD subscales are differentially responsive to SSRIs and SRNIs [14]. Such interactions 
cannot be ruled out, although a far larger body of data would be required to validate them. 
For the present we believe it is reasonable to assume that such effects are relatively minor.  
Our assumption that differences between measurement instruments in responsiveness are 
constant across treatments is, of course, far weaker than the assumption routinely made in 
meta-analyses based on standardized scores from different instruments, namely that all the 
instruments are equally responsive. A more general critique of standardization based on 
these methods was published previously [16].  
Previous meta-analytic work has been restricted to bodies of data in which every test 
instrument has been reported in every study  [13, 14], placing a heavy restriction on the 
number of instruments compared.  Murawski and Miederhof [12] assembled a large body of 
evidence on a range of generic and disease specific instruments. Although they also used 
standardized effect sizes, they looked at within-trial differences between effect sizes, rather 
than ratios, and reported quite extreme levels of between-trial heterogeneity in effect size 
differences. Relatively few studies have attempted formal statistical inference on 
differences in comparative responsiveness, and still fewer have taken account of the 
between-outcome correlation. The method proposed here represents two important 
technical advances in assessing relative responsiveness: first, by exploiting the logical 
transitivity relationship between relative responsiveness parameters we can generate a 
single coherent ranking, based on within-trial information, without requiring every trial to 
report every outcome. Second, the method explicitly takes account of the within-study 
correlations between outcomes. Although we were obliged to use external information 
from the psychometric literature, sensitivity analyses showed that our substantive findings 
were robust against plausible mis-specification of the correlations. 
The proposed method itself has limits. Firstly, because it is based on ratios of effects, it will 
perform best when applied to trials with large effect sizes. The method could become 
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unstable if treatment effects were small. Second, it is necessary to include only studies 
reporting on two or more outcomes, forming a connected network of outcomes. Single 
outcome studies could be included only by introducing cross-study comparisons, which is 
likely to increase the between-study variance of ratios very considerably [12].  
A further limitation is that, while the choice of reference outcome does not alter the fixed 
effects statistical model, this is not strictly true in the case of the random ratios model. If, 
for example, HAMD-17 is chosen as the reference standard, then the accuracy of the   
relative responsiveness ratios can be affected. While this is not a desirable property of the 
model, relative responsiveness point estimates with HAMD-17 as the reference outcome 
differ by no more than a factor of 1.03. Similar insensitivity of results to choice of reference 
test has been reported previously [16]. However, we are working on alternative 
parameterizations which avoids this technical short-coming. 
In spite of these limitations we believe these proposals represent a methodological advance 
in the study of relative responsiveness.  
The current study focuses on relative responsiveness to treatment, ascertained in 
randomized trials. These have the advantage of being based on causal changes due to the 
treatments, while in non-trial settings it less easy to rule out the influence of other factors 
on change scores that are not related to treatment. At the same time, the trial setting 
defines what it is that “responsiveness” is supposed to measure [1], namely the effect of the 
treatment. However, there is no reason why similar methods could not be applied to 
suitably standardize longitudinal measures of responsiveness, as long as the correlation 
structures between different tests at the same time point, between the same test at 
different time points, and between different tests at different time points, are carefully 
taken into account. Whether or not relative responsiveness in these two contexts is the 
same can only be assessed from very large ensembles of data. 
We noted above the connection between relative responsiveness ratios and the “mappings” 
between un-standardized treatment effects on different test instruments [10].   Extensive 
use of mapping from disease specific to generic measures such as EQ-5D is a routine feature 
of health technology assessment, undertaken to estimate health gains on a monetized scale 
[42-44].  
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There is a large literature on mapping between test instruments, also referred to as cross-
walking, test-linking, or test equating [48, 49]  mainly oriented to educational measurement. 
These methods could, again, be readily applied to standardized data.  Among the methods 
available  Item Response Theory, or Rasch Analysis [50], is a particularly powerful technique 
that can be used to highlight differences in the relative responsiveness of test instruments in 
particular parts of their scales. However, all these methods require individual patient data 
on each of the subscales from which the test instruments are formed. This is seldom 
available for more than a single dataset, and our results here show that it is important to 
account for between-study variation.  
For this reason, we feel that the use of aggregate trial data to estimate relative 
responsiveness, is a simple and practical method, although one that could be developed 
further. 
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